Mavacamten,
does it really help with Improved exercise capacity, dyspnea, and NYHA functional class in symptomatic obstructive hypertrophic cardiomyopathy?
research showsMavacamten is rated C despite improving exercise capacity and symptoms over 30 weeks in symptomatic obstructive hypertrophic cardiomyopathy. In the 251-participant, manufacturer-funded EXPLORER-HCM phase 3 trial, the composite functional response occurred in 37% versus 17%, with improvements in peak oxygen consumption, NYHA class, and dyspnea. Evidence remains concentrated on functional and symptom endpoints, while reductions in death or hospitalization are unestablished, invoking the rule ① ceiling of C.
ads claimMarketing may extend exercise and dyspnea improvement into claims of slowed disease progression or longer survival. The established scope is 30-week functional and symptom improvement in selected NYHA class II or III patients.
Useful facts when choosing a product
- Camzyos is a prescription treatment for adults with symptomatic NYHA class II or III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, with specialist dose management.
- It can reduce left ventricular ejection fraction and cause systolic dysfunction and heart failure, requiring echocardiography before and during treatment and restricted distribution under the United States REMS.
- Serious interactions occur with CYP2C19 and CYP3A4 inhibitors or inducers, and potential fetal harm requires effective contraception during treatment and for four months after the last dose.
What the research actually shows
Olivotto and the EXPLORER-HCM investigators randomized 251 patients with NYHA class II or III obstructive hypertrophic cardiomyopathy to mavacamten or placebo for 30 weeks. The primary composite functional response was 37% versus 17%, a 19.4-percentage-point difference, and peak oxygen consumption increased by an additional 1.4 mL/kg/min. At least one NYHA-class improvement occurred in 80 of 123 versus 40 of 128 participants, with improved KCCQ and dyspnea scores. MyoKardia funded the trial, which did not establish effects on death or hospitalization. FDA labeling limits the indication to functional capacity and symptoms and requires echocardiographic monitoring and REMS controls.
Why this is classified as C (55)
The manufacturer-funded EXPLORER-HCM trial showed a 37% versus 17% composite functional response and consistent symptom improvement over 30 weeks, but one trial centered on functional endpoints does not establish death or hospitalization benefit, yielding C with 55 points.
Counterpoint. In appropriately selected and echocardiographically monitored patients, better symptoms and activity capacity can be meaningful. This is not a self-treatment drug.
Rejudgment record. Cross-check applied — Accepted positive EXPLORER-HCM functional and symptom results but applied the rule ① ceiling of C because evidence rests on one manufacturer-funded trial centered on functional endpoints without established death or hospitalization benefit
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved exercise capacity and composite functional response | C | Positive over 30 weeks in EXPLORER-HCM, but based on functional endpoints in one manufacturer-funded trial. |
| Improved NYHA functional class | C | At least one-class improvement was more frequent than with placebo, but durability and hard outcomes remain unestablished. |
| Improved dyspnea | C | Patient-reported dyspnea improved, but this was a 30-week symptom endpoint. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| EXPLORER-HCM investigators (Olivotto I et al.). 2020 | Phase 3 randomized double-blind placebo-controlled trial | 30 | MyoKardia | Composite functional response combining peak oxygen consumption and NYHA class | 37% versus 17%, with improvements in peak oxygen consumption, NYHA class, and dyspnea | Key direct evidence, limited by functional endpoints and a single manufacturer-funded trial |
| U.S. FDA CAMZYOS prescribing information. 2024 | Regulatory approval evidence and safety labeling | 251 | United States Food and Drug Administration regulatory source | Approved efficacy scope, reduced ejection fraction, heart failure, interactions, and fetal risk | Defines the functional and symptom indication and echocardiographic and REMS safeguards | Supports efficacy scope and safety |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Mavacamten x functional and symptom improvement in symptomatic obstructive hypertrophic cardiomyopathy — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/mavacamten-symptomatic-obstructive-hcm-functional-capacity-symptoms/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.